While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
BUSINESS
Kyowa Suspending Alfacalcidol Supply; Chugai Curbs Further Products
Adding to a domino of shipment restrictions on active vitamin D3 analogs, Kyowa Pharmaceutical Industry said on July 20 that it is temporarily pausing the supply of Alfacalcidol Tablets 0.25 μg/0.5 μg/1.0 μg due to manufacturing issues. Many companies, both…
To read the full story
Related Article
- Chugai Lifts Shipment Curbs for Edirol, Easing Active Vitamin D3 Shortages
September 13, 2021
- Osteoporosis Society Greatly Alarmed by Vitamin D3 Analog Shortages, Might Take Further Measures
July 29, 2021
- Prioritize Alfacalcidol Supply for Non-Osteoporosis Indications: MHLW
July 27, 2021
- Scientific Societies Propose Measures for Osteoporosis Treatment amid Shortages of Vitamin D Analogs
July 21, 2021
- Kyosomirai Controls Shipments for Generic Calcitriol Amid Vitamin D3 Preparation Shortage
July 20, 2021
- Teijin Restricting Shipments for Onealfa after Curbs on Edirol
July 13, 2021
- Edirol, Generic Drugs All Now Face Supply Curbs as Nichi-Iko Woes Spill Over
July 8, 2021
- Nichi-Iko Halts Supplies of Some Edirol Generic Products, Re-Supply Expected for September
June 22, 2021
BUSINESS
- Deloitte Proposal to Shed Number of Generics Aims to Spur Industry Consolidation
December 5, 2022
- Mochida Set to Market Lilly’s Ulcerative Colitis Drug Candidate in Japan
December 5, 2022
- 2 Cancer Meds in PIII, Genmab to Rev Up Rep Hiring to Build Sales Regime in Japan
December 2, 2022
- Twymeeg Tops GP Promotion Ranking for 3 Months Running in September: Intage
December 2, 2022
- Healios to Provide Universal Donor Cells to Sumitomo
December 2, 2022
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…